These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 15476538)
1. The final dose of clinical trial designs. Wyllie MG BJU Int; 2004 Oct; 94(6):929-30. PubMed ID: 15476538 [No Abstract] [Full Text] [Related]
2. Discussion of the paper "Adaptive dose-ranging designs". Burman CF J Biopharm Stat; 2007; 17(6):1005-11; discussion 1029-32. PubMed ID: 18027210 [No Abstract] [Full Text] [Related]
3. Discussion of "The White Paper of the PhRMA Working Group on adaptive dose-ranging designs". Hemmings R J Biopharm Stat; 2007; 17(6):1021-7; discussion 1029-32. PubMed ID: 18027213 [No Abstract] [Full Text] [Related]
4. Discussion of the "White Paper of the PhRMA Working Group on adaptive dose-ranging designs". Grieve AP J Biopharm Stat; 2007; 17(6):997-1004; discussion 1029-32. PubMed ID: 18027209 [No Abstract] [Full Text] [Related]
5. Discussion of the "White Paper of the PhRMA PISC Working Group on adaptive dose-ranging designs". Leonov S J Biopharm Stat; 2007; 17(6):1013-4; discussion 1029-32. PubMed ID: 18027211 [No Abstract] [Full Text] [Related]
6. Evaluation and recommendations on adaptive dose-ranging trials: highlights from the PhRMA Adaptive Dose-Ranging Studies Working Group. Pinheiro J J Clin Pharmacol; 2010 Sep; 50(9 Suppl):47S-49S. PubMed ID: 20881216 [No Abstract] [Full Text] [Related]
7. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
8. Strategies for designing clinical trials for oligonucleotide therapeutics. Wacheck V Drug Discov Today; 2004 Nov; 9(21):918-23. PubMed ID: 15501726 [TBL] [Abstract][Full Text] [Related]
11. Improving efficiency of ALS clinical trials using lead-in designs. Moore DH; Miller RG Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():57-60. PubMed ID: 15512875 [TBL] [Abstract][Full Text] [Related]
12. Combining proof-of-concept with dose-finding: utilization of adaptive designs in migraine clinical trials. Sagkriotis A; Scholpp J Cephalalgia; 2008 Aug; 28(8):805-12. PubMed ID: 18513264 [TBL] [Abstract][Full Text] [Related]
13. FDA signals it's open to drug trials that shift midcourse. Mathews AW Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817 [No Abstract] [Full Text] [Related]
14. The use of genomics in clinical trial design. Simon R Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477 [TBL] [Abstract][Full Text] [Related]
15. The need for more efficient trial designs. Golub HL Stat Med; 2006 Oct; 25(19):3231-5; discussion 3313-4, 3326-47. PubMed ID: 16819752 [TBL] [Abstract][Full Text] [Related]
16. Small study on industry trial sponsorship leads to big questions about quality and bias. Twombly R J Natl Cancer Inst; 2007 Jul; 99(13):988-90. PubMed ID: 17596566 [No Abstract] [Full Text] [Related]
17. Estimation in flexible two stage designs. Brannath W; König F; Bauer P Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489 [TBL] [Abstract][Full Text] [Related]